Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2013 | 450.04 Thousand USD | -15.2% |
| 2012 | 530.72 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 100.0% |
| 2000 | -24.9 Thousand USD | -112.45% |
| 1999 | 200 Thousand USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 100.0% |
| 1996 | -100 Thousand USD | 66.67% |
| 1995 | -300 Thousand USD | -400.0% |
| 1994 | 100 Thousand USD | 103.13% |
| 1993 | -3.2 Million USD | -500.0% |
| 1992 | 800 Thousand USD | -80.95% |
| 1991 | 4.2 Million USD | -20.75% |
| 1990 | 5.3 Million USD | 130.43% |
| 1989 | 2.3 Million USD | 475.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2014 Q1 | 17.51 Thousand USD | -95.56% |
| 2014 Q2 | 17.51 Thousand USD | 0.01% |
| 2013 Q2 | 18.43 Thousand USD | 0.0% |
| 2013 Q4 | 394.74 Thousand USD | 2041.64% |
| 2013 FY | 450.04 Thousand USD | -15.2% |
| 2013 Q3 | 18.43 Thousand USD | 0.0% |
| 2013 Q1 | 18.43 Thousand USD | 0.0% |
| 2012 Q2 | 250 Thousand USD | 0.0% |
| 2012 Q4 | 18.43 Thousand USD | 50.0% |
| 2012 FY | 530.72 Thousand USD | 0.0% |
| 2012 Q1 | 250 Thousand USD | 0.0% |
| 2012 Q3 | 12.28 Thousand USD | -95.08% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q1 | 1.00 USD | 0.0% |
| 2002 Q2 | - USD | -100.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q3 | - USD | -100.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 100.0% |
| 2001 Q1 | 1.00 USD | 100.03% |
| 2001 Q2 | 1.00 USD | 0.0% |
| 2000 Q4 | -3024.00 USD | 24.94% |
| 2000 Q2 | -2886.00 USD | 80.72% |
| 2000 Q1 | -14.96 Thousand USD | 0.0% |
| 2000 FY | -24.9 Thousand USD | -112.45% |
| 2000 Q3 | -4029.00 USD | -39.6% |
| 1999 Q3 | 200 Thousand USD | 100.0% |
| 1999 FY | 200 Thousand USD | 0.0% |
| 1999 Q4 | - USD | -100.0% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1999 Q1 | 100 Thousand USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q1 | -100 Thousand USD | 0.0% |
| 1998 Q4 | - USD | -100.0% |
| 1998 Q2 | 100 Thousand USD | 200.0% |
| 1997 Q1 | 100 Thousand USD | -90.0% |
| 1997 FY | - USD | 100.0% |
| 1997 Q4 | - USD | -100.0% |
| 1997 Q3 | 100 Thousand USD | 0.0% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1996 Q2 | -400 Thousand USD | -300.0% |
| 1996 FY | -100 Thousand USD | 66.67% |
| 1996 Q4 | 1 Million USD | 266.67% |
| 1996 Q3 | -600 Thousand USD | -50.0% |
| 1996 Q1 | -100 Thousand USD | -100.93% |
| 1995 Q3 | 300 Thousand USD | 102.88% |
| 1995 Q1 | 100 Thousand USD | 0.0% |
| 1995 FY | -300 Thousand USD | -400.0% |
| 1995 Q4 | 10.8 Million USD | 3500.0% |
| 1995 Q2 | -10.4 Million USD | -10500.0% |
| 1994 Q2 | - USD | 100.0% |
| 1994 Q1 | -2.4 Million USD | -14.29% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 FY | 100 Thousand USD | 103.13% |
| 1993 Q3 | -300 Thousand USD | -50.0% |
| 1993 Q1 | -300 Thousand USD | -250.0% |
| 1993 FY | -3.2 Million USD | -500.0% |
| 1993 Q4 | -2.1 Million USD | -600.0% |
| 1993 Q2 | -200 Thousand USD | 33.33% |
| 1992 Q2 | -2 Million USD | 13.04% |
| 1992 Q4 | 200 Thousand USD | -60.0% |
| 1992 Q3 | 500 Thousand USD | 125.0% |
| 1992 Q1 | -2.3 Million USD | -121.7% |
| 1992 FY | 800 Thousand USD | -80.95% |
| 1991 Q1 | -2.2 Million USD | -540.0% |
| 1991 Q3 | -1.9 Million USD | -258.33% |
| 1991 Q2 | 1.2 Million USD | 154.55% |
| 1991 FY | 4.2 Million USD | -20.75% |
| 1991 Q4 | 10.6 Million USD | 657.89% |
| 1990 Q4 | 500 Thousand USD | -61.54% |
| 1990 Q2 | 3.7 Million USD | 3600.0% |
| 1990 Q1 | 100 Thousand USD | -75.0% |
| 1990 Q3 | 1.3 Million USD | -64.86% |
| 1990 FY | 5.3 Million USD | 130.43% |
| 1989 FY | 2.3 Million USD | 475.0% |
| 1989 Q3 | 1.1 Million USD | 10.0% |
| 1989 Q1 | 100 Thousand USD | 0.0% |
| 1989 Q2 | 1 Million USD | 900.0% |
| 1989 Q4 | 400 Thousand USD | -63.64% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 18551.948% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 96.155% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 240.855% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.622% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 101.744% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 1032.558% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 462.205% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 97.0% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -14408.156% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 95.405% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -584.705% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 1417.842% |
| Mesoblast Limited | -35.16 Million USD | 101.28% |
| Marizyme, Inc. | 457.7 Thousand USD | 1.673% |
| Genus plc | 178.7 Million USD | 99.748% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.796% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -623.239% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -9.722% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 4191.3% |
| ContraFect Corporation | -154 Thousand USD | 392.236% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 1000.086% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -486.291% |
| IMV Inc. | -962.29 Thousand USD | 146.768% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 216.14% |
| MultiCell Technologies, Inc. | 49.32 USD | -912395.945% |
| ONE Bio Corp. | 20.12 Million USD | 97.764% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 98.882% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -820.333% |
| Q BioMed Inc. | -8988.00 USD | 5107.154% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 98.407% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 3017.81% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 98.985% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 139.423% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -542.919% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 9188.106% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -220.315% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 561.512% |
| GB Sciences, Inc. | -624.00 USD | 72222.276% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 623.135% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.994% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 216466.827% |
| Enzolytics Inc. | 30.7 Thousand USD | -1365.556% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 6.714% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.959% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 187.47% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 27.105% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.89% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 5181.786% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 636.73% |
| Kadimastem Ltd | -630.13 Thousand USD | 171.42% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 54.448% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 95.317% |
| BioStem Technologies, Inc. | 15.42 Million USD | 97.082% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 3902.645% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -154.895% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -154.895% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 66.839% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 1651.872% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| SYBLEU INC | 11.69 Thousand USD | -3747.837% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 90.233% |
| Bioxytran, Inc. | -8285.00 USD | 5532.022% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 220.655% |
| Neutra Corp. | 14.33 Thousand USD | -3039.47% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 648.833% |
| PureTech Health plc | -1.6 Million USD | 128.075% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 144.949% |
| IXICO plc | 3.27 Million USD | 86.237% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 164.848% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 125.128% |
| CSL Limited | 7.7 Billion USD | 99.994% |
| Cellectis S.A. | 18 Thousand USD | -2400.239% |